Evotec (EVO) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Evotec (EVO) over the past year, losing 15.0% versus a loss of 58.9%. Over five years, MNPR leads with a +241.3% price change compared with -92.9% for EVO. Monopar Therapeutics is the larger company by market cap ($563.7 million vs $558.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | MNPR |
|---|---|---|
| Share price | $1.57 | $83.98 |
| Market cap | $557.96M | $563.69M |
| 1-day change | -2.48% | +0.24% |
| YTD return | -47.73% | +28.30% |
| 1-year return | -58.93% | -14.96% |
| 5-year return | -92.87% | +241.26% |
| EPS (TTM) | $-0.64 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.27 | $124.82 |
| 52-week low | $1.50 | $50.07 |
| Distance from 52-week high | -63.23% | -32.72% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +164.97% | +54.70% |
| Average volume | 103.98K | 215.52K |
| Shares outstanding | 355.39M | 6.71M |
| Employees | 4,461 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed EVO by 44.0 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
EVO vs MNPR FAQ
Which is bigger, Evotec or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $563.69M compared with $557.96M for Evotec (EVO).
Which stock has performed better over the past year, EVO or MNPR?
MNPR returned -14.96% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.